

COLUMBIA UNIVERSITY IRVING MEDICAL CENTER



Background

5.

- Cytomegalovirus (CMV) antigens are reported in >90% of GBMs
- 'Foreign' tumor-associated viral antigens are inherently immunogenic
- gB and pp65 antigens are the most frequent CMV targets for CD4+ and CD8+ T-cells
 - CD8+ T cells are critical for killing of tumor cells
 - CD4+ effector memory (CCR7-CD45RA-) cells preferentially migrate to the tumor microenvironment and are critical for CD8+ T cell persistence and function
- Targeting CMV as a foreign viral antigen has the potential to harness, re-stimulate, and re-focus pre-existing anti-CMV immunity to clear CMV+ tumors
- VBI-1901, a bivalent gB/pp65 enveloped virus-like particle (eVLP), is currently in the Phase IIa portion of an ongoing Phase I/IIa clinical study

About VBI-1901

Rationally-designed vaccine immuno-therapeutic for CMV+ solid tumors

Schematic	
Antibody Target	gB
T Cell Targets	gB (CD4+), pp65 (CD8+)
Target Indication	Treatment of CMV+ solid tumors, notably gl
Rationale	Targets multiple antigens, each with multiple promote broad immunity & avoid tumor of the second second terms and the second sec
Adjuvant	GM-CSF or GSK's AS01 _B

Phase I/IIa Trial Design

Two-part, multi-center, open-label, dose-escalation study of VBI-1901 in patients with recurrent GBM

ClinicalTrials.Gov identifier: NCT03382977

Phase I : Dose-Escalation Phase Recurrent GBM (any #) Study Arm 3: High Dose (n=6) 10.0 µg + GM-CSF Study Arm 2: Int. Dose (n=6) 2.0 µg + GM-CSF Study Arm 1: Low Dose (n=6) 0.4 µg + GM-CSF

Outcome Measures : Phase I/IIa

- Safety
- Immunogenicity
- Tumor and clinical responses
- Quality of life

Phase IIa: Extension Phase Recurrent GBM (1st only) *Study Arm 1:* n=10 10.0 µg + GM-CSF (i.d.) Study Arm 2: n=10 10.0 μg + GSK's AS01_B (i.m.)


Patient Demographics : Phase IIa

- **GM-CSF arm :** median age 58 (33-67 yrs) • 4 men; 6 women
- **AS01_B arm :** median age 65 (40-67 yrs) • 7 men; 3 women

Evaluation of GM-CSF and AS01_B Adjuvants in a Phase I/IIa Trial of a Therapeutic CMV Vaccine (VBI-1901) Against Recurrent Glioblastoma (GBM)

PY Wen¹, DA Reardon¹, D Forst², EQ Lee¹, FM Iwamoto³, F Diaz-Mitoma⁴, DE Anderson⁴, AB Lassman³

¹Dana-Farber Cancer Institute, ³Pappas Center for Neuro-Oncology, Massachusetts General Cancer Center, ²Dept. of Neurology and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, ⁴VBI Vaccines Inc.



Abstract No. 2047



